

Multi-targeting of New Biologic Drugs

George Wang, Ph.D.
VP of Discovery and Preclinical Service

November 22nd, 2023



WuXi Biologics
Global Solution Provider



Stock Code: 2269.HK

All rights are reserved. The information in this PPT shall not be considered as information disclosure or investment advice.

This document is strictly confidential to the recipient only, and may not be copied, reproduced, redistributed, disseminated, or used or disclosed to any other person, or published, in whole or in part, for any other purpose without written permission from the Company and the author.

This document has been prepared using information provided by the Company but without further investigation cannot be warranted as to its accuracy or completeness. Certain data in this document was obtained from external data sources, and the Company has not verified such data with independent sources. Accordingly, the Company makes no representations as to the accuracy or completeness of that data. Such data involves risks and uncertainties and is subject to change based on various factors. The use of registered trademarks, commercial trademarks and logos or photographic materials within this document are exclusively for illustrative purposes and are not meant to violate the rights of the creators and/or applicable intellectual property laws.

Multi-targeting as new wave of innovative drugs




MULTISPECIFIC DRUGS HERALD A NEW ERA OF BIOPHARMACEUTICAL INNOVATION


Raymond J. Deshaies. Nature 2020

Multi-specific/functional Antibody Drugs Approved in Recent Years

Approved Antibody Drugs




Antibody as Building Block Multi-targeting Biologics



Two Screening Funnels of Innovative Biologic Drugs

Functionality


Binding/Blocking
Specificity
Epitope
Cross-reactivity
- Homologue
- Parologue
Biochemical assays
Cellular assays
Rodent PK
Cyno PK
PD models
Efficacy models
Toxicity




Developability

Expression level
Purity
Solubility
PTM & Stress Test
Physical Stability
- Colloidal Stability
- Thermal Stability
- Freeze-Thaw Stability
Serum Stability
Preliminary Scalable
Manufacturability
Preliminary Formulation
Ability
Immunogenicity Risk

WuXi Biologics' Discovery Service from Concept to IND



Enable Clients Advancing Projects to Clinical Development & Approval



Thank You

www.wuxibiologics.com/discovery

info@wuxibiologics.com

Learn More

